Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 10/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 10/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.32 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599750 | 0.82 | ALDH1A1 (0.39) | PARP1PIM1PIM3ALDH1A1IMPDH2 | |
| SCHEMBL12182211 | 0.82 | TRIM24 (0.40) | PARP1PIM1PIM3ALDH1A1IMPDH2 | |
| SCHEMBL2599738 | 0.81 | PARP1 (0.37) | PARP1PIM1PIM3ALDH1A1IMPDH2 | |
| SCHEMBL671667 | 0.79 | CYP2A6 (0.40) | PIM1PIM3ALDH1A1IMPDH2PIM2 | |
| SCHEMBL22955077 | 0.74 | ALDH1A1 (0.39) | PARP1PIM1PIM3ALDH1A1IMPDH2 | |
| SCHEMBL2599810 | 0.72 | ALDH1A1 (0.40) | PARP1PIM1PIM3ALDH1A1IMPDH2 | |
| SCHEMBL2599812 | 0.71 | ALDH1A1 (0.39) | ALDH1A1LMNA | |
| SCHEMBL10236175 | 0.70 | ALDH1A1 (0.43) | ALDH1A1LMNA | |
| SCHEMBL2599820 | 0.70 | CYP2A6 (0.40) | PIM1PIM3ALDH1A1IMPDH2CYP2A6 | |
| SCHEMBL1786483 | 0.69 | KDM4E (0.52) | PIM1PIM3ALDH1A1IMPDH2PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571356-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| WO-2011146324-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | SSTR5, SSTR2, SSTR1 | PARP1 3607/4885PIM1 3849/4885PIM3 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.